Vimian Group AB
STO:VIMIAN
Net Margin
Vimian Group AB
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| SE |
V
|
Vimian Group AB
STO:VIMIAN
|
18.4B SEK |
5%
|
|
| CH |
|
Alcon AG
SIX:ALC
|
34.5B CHF |
11%
|
|
| JP |
|
Hoya Corp
TSE:7741
|
6.2T JPY |
23%
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
136.8B DKK |
16%
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
14.1B USD |
10%
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
5.8B CHF |
12%
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.9B GBP |
8%
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
43.1B CNY |
40%
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
5B USD |
9%
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
4.9B USD |
-8%
|
|
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5B USD |
17%
|
Vimian Group AB
Glance View
Vimian Group AB is a relatively new player making waves in the veterinary and animal health industries. Founded in Sweden, Vimian is structured as a conglomerate composed of specialized subsidiaries focused on different niche markets within veterinary services, diagnostics, and technology. This strategic structure enables the company to operate across various segments such as Veterinary Services, Specialty Pharma, MedTech, and Diagnostics, achieving a holistic approach to animal healthcare. By acquiring and partnering with innovative companies globally, Vimian capitalizes on synergies and cross-market opportunities, ensuring a competitive edge in each of its operational fields. The company’s diverse portfolio allows it to cater not only to pet owners and veterinary professionals but also to livestock industries, ensuring comprehensive coverage in the growing market of animal welfare and health. Vimian’s revenue streams are multi-faceted, generated from a blend of product sales, subscriptions, and service fees. For instance, within its Specialty Pharma segment, the company develops and sells pharmaceutical products designed to treat common and specialty conditions in animals, thus generating continuous revenue from veterinary practices worldwide. In the MedTech segment, Vimian offers cutting-edge medical devices and equipment, enhancing veterinary surgical and diagnostic capabilities, which drives sales. Meanwhile, their Diagnostics division provides innovative testing solutions that help veterinarians identify and treat animal diseases accurately, offering another lucrative revenue stream. This multi-pronged business model not only mitigates risk through diversification but also positions Vimian as a key player in meeting the rapidly evolving demands of animal health and care.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Vimian Group AB's most recent financial statements, the company has Net Margin of 4.9%.
You don't have any saved screeners yet